Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines

Daniel A. Pollyea; Dale Bixby; Alexander Perl; Vijaya Raj Bhatt; Jessica K. Altman; Frederick R. Appelbaum; Marcos De Lima; Amir T. Fathi; James M. Foran; Ivana Gojo; Aric C. Hall; Meagan Jacoby; Jeffrey Lancet; Gabriel Mannis; Guido Marcucci; Michael G. Martin; Alice Mims; Jadee Neff; Reza Nejati; Rebecca Olin; Mary Elizabeth Percival; Thomas Prebet; Amanda Przespolewski; Dinesh Rao; Farhad Ravandi-Kashani; Paul J. Shami; Richard M. Stone; Stephen A. Strickland; Kendra Sweet; Pankit Vachhani; Matthew Wieduwilt; Kristina M. Gregory; Ndiya Ogba; Martin S. Tallman

doi:10.6004/JNCCN.2021.0002

Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines

Daniel A. Pollyea, Dale Bixby, Alexander Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos De Lima, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Jadee Neff, Reza Nejati, Rebecca OlinMary Elizabeth Percival, Thomas Prebet, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi-Kashani, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Kendra Sweet, Pankit Vachhani, Matthew Wieduwilt, Kristina M. Gregory, Ndiya Ogba, Martin S. Tallman

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

230 Scopus citations

Abstract

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.

Original language	English (US)
Pages (from-to)	16-27
Number of pages	12
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	19
Issue number	1
DOIs	https://doi.org/10.6004/JNCCN.2021.0002
State	Published - Jan 2021

Funding

This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics. Vijaya Raj Bhatt, MBBS, Panel Member, has disclosed that he receives grant/research support from AbbVie, Inc., Incyte Corporation, Jazz Pharmaceuticals Inc., Tolero, and Pfizer Inc.; consulting fees from AbbVie, Inc., Genentech, Inc., Incyte Corporation, Omeros, Rigel, and Takeda Pharmaceuticals North America, Inc.; and other financial benefit from Oncoceutics.

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/JNCCN.2021.0002

Cite this

Pollyea, D. A., Bixby, D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., Lima, M. D., Fathi, A. T., Foran, J. M., Gojo, I., Hall, A. C., Jacoby, M., Lancet, J., Mannis, G., Marcucci, G., Martin, M. G., Mims, A., Neff, J., Nejati, R., ... Tallman, M. S. (2021). Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 19(1), 16-27. https://doi.org/10.6004/JNCCN.2021.0002

@article{84a2bc4d319c46f5b1e29a09b28968dc,

title = "Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.",

author = "Pollyea, {Daniel A.} and Dale Bixby and Alexander Perl and Bhatt, {Vijaya Raj} and Altman, {Jessica K.} and Appelbaum, {Frederick R.} and Lima, {Marcos De} and Fathi, {Amir T.} and Foran, {James M.} and Ivana Gojo and Hall, {Aric C.} and Meagan Jacoby and Jeffrey Lancet and Gabriel Mannis and Guido Marcucci and Martin, {Michael G.} and Alice Mims and Jadee Neff and Reza Nejati and Rebecca Olin and Percival, {Mary Elizabeth} and Thomas Prebet and Amanda Przespolewski and Dinesh Rao and Farhad Ravandi-Kashani and Shami, {Paul J.} and Stone, {Richard M.} and Strickland, {Stephen A.} and Kendra Sweet and Pankit Vachhani and Matthew Wieduwilt and Gregory, {Kristina M.} and Ndiya Ogba and Tallman, {Martin S.}",

note = "Publisher Copyright: {\textcopyright} JNCCN-Journal of the National Comprehensive Cancer Network.",

year = "2021",

month = jan,

doi = "10.6004/JNCCN.2021.0002",

language = "English (US)",

volume = "19",

pages = "16--27",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "1",

}

Pollyea, DA, Bixby, D, Perl, A, Bhatt, VR, Altman, JK, Appelbaum, FR, Lima, MD, Fathi, AT, Foran, JM, Gojo, I, Hall, AC, Jacoby, M, Lancet, J, Mannis, G, Marcucci, G, Martin, MG, Mims, A, Neff, J, Nejati, R, Olin, R, Percival, ME, Prebet, T, Przespolewski, A, Rao, D, Ravandi-Kashani, F, Shami, PJ, Stone, RM, Strickland, SA, Sweet, K, Vachhani, P, Wieduwilt, M, Gregory, KM, Ogba, N & Tallman, MS 2021, 'Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 19, no. 1, pp. 16-27. https://doi.org/10.6004/JNCCN.2021.0002

TY - JOUR

T1 - Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines

AU - Pollyea, Daniel A.

AU - Bixby, Dale

AU - Perl, Alexander

AU - Bhatt, Vijaya Raj

AU - Altman, Jessica K.

AU - Appelbaum, Frederick R.

AU - Lima, Marcos De

AU - Fathi, Amir T.

AU - Foran, James M.

AU - Gojo, Ivana

AU - Hall, Aric C.

AU - Jacoby, Meagan

AU - Lancet, Jeffrey

AU - Mannis, Gabriel

AU - Marcucci, Guido

AU - Martin, Michael G.

AU - Mims, Alice

AU - Neff, Jadee

AU - Nejati, Reza

AU - Olin, Rebecca

AU - Percival, Mary Elizabeth

AU - Prebet, Thomas

AU - Przespolewski, Amanda

AU - Rao, Dinesh

AU - Ravandi-Kashani, Farhad

AU - Shami, Paul J.

AU - Stone, Richard M.

AU - Strickland, Stephen A.

AU - Sweet, Kendra

AU - Vachhani, Pankit

AU - Wieduwilt, Matthew

AU - Gregory, Kristina M.

AU - Ogba, Ndiya

AU - Tallman, Martin S.

PY - 2021/1

Y1 - 2021/1

N2 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.

AB - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.

UR - http://www.scopus.com/inward/record.url?scp=85099750763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099750763&partnerID=8YFLogxK

U2 - 10.6004/JNCCN.2021.0002

DO - 10.6004/JNCCN.2021.0002

M3 - Article

C2 - 33406488

AN - SCOPUS:85099750763

SN - 1540-1405

VL - 19

SP - 16

EP - 27

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

ER -

Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this